BioNTech SE Sponsored ADR (NASDAQ:BNTX) Stock Has Consensus Target Price of $126.00

Key Points

• Analysts maintain a “Moderate Buy” consensus on BioNTech, with 12 buy ratings, five holds, one sell, and one strong buy among 19 brokerages. The average 12-month price target is $126, versus the reported share price of $96.90.
• Recent quarterly results were weaker than expected: BioNTech reported an EPS loss of $2.53 versus the $2.40 consensus estimate, while revenue fell 59.5% year over year to $122.31 million.
• Insider selling increased, including CEO Ugur Sahin’s sale of 46,000 shares worth approximately $4.63 million. Insiders sold 627,000 shares during the quarter, while institutional investors—including Bank of America and First Trust Advisors—expanded their positions.

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the nineteen brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation, twelve have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $126.00.

A number of analysts recently commented on BNTX shares. Berenberg Bank set a $140.00 price target on BioNTech in a research note on Wednesday, September 16th. Citigroup cut their price objective on shares of BioNTech from $130.00 to $125.00 and set a "buy" rating on the stock in a report on Wednesday, August 5th. Canaccord Genuity Group dropped their price target on BioNTech from $142.00 to $136.00 and set a "buy" rating on the stock in a research report on Monday, August 31st. Wall Street Zen downgraded BioNTech from a "hold" rating to a "sell" rating in a research note on Saturday, August 8th. Finally, Sanford C. Bernstein reiterated a "market perform" rating on shares of BioNTech in a research note on Friday, June 5th.

Insider Transactions at BioNTech

In other BioNTech news, CEO Ugur Sahin sold 46,000 shares of the stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $100.72, for a total transaction of $4,633,120.00. Following the sale, the chief executive officer directly owned 410,209 shares in the company, valued at approximately $41,316,250.48. This trade represents a 10.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 627,000 shares of company stock valued at $61,967,005. Corporate insiders own 19.20% of the company's stock.

Institutional Trading of BioNTech

A number of institutional investors have recently made changes to their positions in the stock. Flossbach Von Storch SE bought a new position in BioNTech during the second quarter valued at approximately $207,142,000. Bank of America Corp DE raised its stake in BioNTech by 22.6% during the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company's stock valued at $80,261,000 after buying an additional 166,432 shares during the last quarter. First Trust Advisors LP raised its stake in BioNTech by 116.0% during the 1st quarter. First Trust Advisors LP now owns 839,991 shares of the company's stock valued at $74,658,000 after buying an additional 451,124 shares during the last quarter. Assenagon Asset Management S.A. bought a new position in shares of BioNTech during the 2nd quarter valued at $39,385,000. Finally, CenterBook Partners LP boosted its stake in shares of BioNTech by 27.3% in the 4th quarter. CenterBook Partners LP now owns 236,175 shares of the company's stock worth $22,484,000 after buying an additional 50,684 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company's stock.

BioNTech Price Performance

Shares of BioNTech stock opened at $96.90 on Friday. The firm has a market cap of $24.50 billion, a PE ratio of -12.38 and a beta of 1.25. BioNTech has a 12-month low of $79.52 and a 12-month high of $124.00. The company has a quick ratio of 7.80, a current ratio of 7.85 and a debt-to-equity ratio of 0.01. The company's fifty day simple moving average is $98.81 and its two-hundred day simple moving average is $95.01.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The firm had revenue of $122.31 million for the quarter, compared to the consensus estimate of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The business's revenue was down 59.5% on a year-over-year basis. During the same period last year, the company posted ($1.60) earnings per share. As a group, equities analysts expect that BioNTech will post -6.37 EPS for the current year.

About BioNTech

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company's research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.